The research team, led by Xiaoqiang Zhang and corresponding authors Guangyan Ji and Ling-quan Kong, searched five major international databases—PubMed, Embase, Web of Science, the Cochrane Library—and Chinese databases including CNKI and the China Biology Medicine database, covering the literature from its beginnings through 16 October 2025. From that sweep, twenty-seven observational studies met the inclusion criteria. The work was registered in advance on PROSPERO under CRD420261328733 and followed established reporting frameworks for meta-analyses of observational studies, lending methodological weight to conclusions drawn from a heterogeneous body of clinical literature.

The headline statistic concerns prevalence. Across eleven studies that relied exclusively on computed tomography and collectively included 13,363 breast cancer patients, the pooled prevalence of pulmonary nodules was 13.1 percent, with a 95 percent confidence interval stretching from 5.6 to 27.4 percent. That wide interval reflects substantial variation between individual studies, a familiar feature of research that pools real-world imaging data collected with different scanners, slice thicknesses, and nodule-size thresholds. When the analysis was restricted to nodules detected at initial staging, prevalence settled at 9.8 percent, while nodules found during follow-up imaging were slightly more common at 12.5 percent, though the follow-up estimate carried enormous statistical uncertainty.

Prevalence, however, is only the opening question. The clinically decisive issue is what those nodules actually are, and answering it requires tissue. Across seven studies encompassing 3,163 patients found to have pulmonary nodules, only 15.3 percent underwent any invasive diagnostic intervention—a biopsy, resection, or other procedure capable of yielding a pathological diagnosis. The confidence interval, from 6.6 to 31.6 percent, again signals wide variation in practice, but the central message is unambiguous: the overwhelming majority of nodules detected in breast cancer patients are never definitively characterized, leaving their true nature a matter of inference rather than proof.

Among the nodules that were pathologically confirmed—drawn from seventeen studies totaling 1,223 cases—the pathological spectrum proved strikingly diverse. Primary lung cancer accounted for 46.3 percent of confirmed nodules, metastatic breast cancer for 37.6 percent, and benign disease for 17.5 percent. In other words, when a nodule in a breast cancer patient is finally sampled, it is more likely to be a new, independent lung cancer than a metastasis, and nearly one in five confirmed nodules turns out to be entirely harmless. Each of these categories carries radically different implications for treatment, prognosis, and follow-up intensity.

The technical logic behind this distribution is worth unpacking. Breast cancer is one of the most common malignancies worldwide, and patients are frequently imaged with chest CT at diagnosis and throughout surveillance, precisely the population in which small pulmonary nodules are incidentally found in the general population as well. Meanwhile, shared risk factors—most notably tobacco smoking history, along with age—elevate the baseline risk of primary lung cancer in some patient subgroups. The lung is also a favored site of breast cancer metastasis, which is why the metastatic presumption is so entrenched. The meta-analysis does not deny that risk; it quantifies it, showing that metastasis is common but not dominant once tissue diagnosis is obtained.

Why do so few nodules undergo biopsy? The review’s intervention figures point to a tangle of clinical conservatism. Many nodules are small, often below the size threshold where percutaneous or bronchoscopic sampling is technically reliable, and guidelines from bodies such as the American College of Chest Physicians typically recommend surveillance imaging for small, low-suspicion nodules even in patients without cancer. In oncology patients, clinicians may also weigh the risks of invasive procedures against the assumption that, in a stage IV context, the finding will not change systemic therapy. Yet the analysis suggests that assumption deserves scrutiny, because a primary lung cancer may warrant surgical resection or targeted therapy, and a benign nodule may warrant nothing at all beyond routine follow-up.

The heterogeneity embedded in the pooled estimates deserves honest acknowledgment. A confidence interval as wide as 0.1 to 96.2 percent, seen in the follow-up prevalence estimate, means the underlying studies disagree profoundly—likely because of differences in imaging protocols, patient staging distributions, and whether sub-centimeter nodules were counted. Random-effects modeling, which the authors employed using restricted maximum likelihood estimation, explicitly accommodates this between-study variability rather than pretending a single true prevalence exists. For readers, the practical takeaway is that the point estimates are best understood as central tendencies across diverse clinical settings, not as universal constants.

The clinical implication the authors draw is measured but firm: pulmonary nodules in breast cancer patients should not be presumed metastatic. Instead, they argue, clinical assessment should weigh alternative diagnoses and consider whether tissue confirmation would actually change management. That framing aligns with a broader movement in oncology toward molecularly and histologically verified decision-making, particularly as treatments for primary lung cancer—EGFR and ALK targeted therapies, immunotherapy, stereotactic body radiotherapy—diverge sharply from regimens for metastatic breast cancer. A wrong presumption of metastasis could, in principle, deny a patient curative-intent treatment for a second primary tumor.

For patients, the numbers offer a recalibrated perspective on a frightening scan result. Roughly one in eight breast cancer patients undergoing chest CT will have a pulmonary nodule reported, but only a minority of those nodules will ever be proven to be anything at all, and when they are, benign disease and new primary lung cancer together account for nearly two-thirds of confirmed cases. The study, supported by the Science-Health Joint Medical Scientific Research Project of Chongqing, does not tell any individual patient what her nodule means—that remains the domain of multidisciplinary evaluation involving thoracic radiology, pulmonology, and oncology. What it does provide is the population-level evidence base that such evaluations have long lacked, replacing reflexive pessimism with quantified probabilities and a clear argument for letting tissue, not assumption, guide the next step.

Subject of Research: Prevalence and pathological spectrum of pulmonary nodules detected in breast cancer patients

Article Title: Pulmonary nodules in breast cancer patients: prevalence, diagnostic intervention rate, and pathologic spectrum

Article References: Zhang, X., Tie, H., Mu, L., Mo, L., Jiao, J., Ji, G., & Kong, L.-Q. (2026). Pulmonary nodules in breast cancer patients: prevalence, diagnostic intervention rate, and pathologic spectrum. BMC Cancer. https://doi.org/10.1186/s12885-026-17034-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17034-7

Keywords: breast cancer, pulmonary nodules, metastasis, primary lung cancer, benign nodules, CT imaging, biopsy, meta-analysis, oncology, cancer staging, diagnostic intervention, BMC Cancer